PMID- 37428211
OWN - NLM
STAT- MEDLINE
DCOM- 20231004
LR  - 20231004
IS  - 1743-9159 (Electronic)
IS  - 1743-9191 (Print)
IS  - 1743-9159 (Linking)
VI  - 109
IP  - 9
DP  - 2023 Sep 1
TI  - A multicenter, single-arm, open study of neoadjuvant or conversion atezolizumab 
      in combination with chemotherapy in resectable small cell lung cancer (Cohort 
      Study).
PG  - 2641-2649
LID - 10.1097/JS9.0000000000000501 [doi]
AB  - BACKGROUND: This study aimed to investigate the prospects of using chemotherapy 
      in combination with atezolizumab in the neoadjuvant or conversion treatment of 
      small cell lung cancer (SCLC). METHODS: Prior to surgery, untreated patients with 
      limited-stage SCLC received three cycles of neoadjuvant or conversion 
      atezolizumab combined with chemotherapy of etoposide and platinum. The primary 
      endpoint of the trial was pathological complete response (pCR) in the 
      per-protocol (PP) cohort. In addition, safety was assessed based on 
      treatment-related adverse events (AEs) and postoperative complications. RESULTS: 
      Overall, 13 of 17 patients (including 14 males and 3 females) underwent surgery. 
      In the PP cohort, pCR and major pathological response were observed in 8 (8/13, 
      61.5%) and 12 (12/13, 92.3%) patients, respectively. According to the 
      intention-to-treat (ITT) analysis, the pCR and major pathological response in the 
      ITT cohort were 47.1% (8/17) and 70.6% (12/17), respectively. In addition, an 
      overall response rate of 100% was recorded in the PP cohort. Moreover, 15 (15/17, 
      88.2%) patients and 1 (1/17, 5.9%) in the ITT cohort attained partial remission 
      (PR), and complete remission, respectively, with an overall response rate of 
      94.1%. The median overall survival of the patients of pCR and the median 
      event-free survival of the patients on surgery had not achieved. However, the 
      median overall survival of the patients of non-pCR was 18.2 months and the median 
      event-free survival of the nonsurgical patients was 9.5 months. During the 
      neoadjuvant treatment, the incidence of grade 3 or higher AEs was 58.8% (10/17). 
      Additionally, three patients (17.6%) developed immune-related adverse event 
      (grades 1-2). CONCLUSION: In patients with SCLC, neoadjuvant or conversion 
      atezolizumab combined with chemotherapy significantly improved pCR with 
      manageable AEs. Therefore, this regimen may be considered a safe and effective 
      treatment for SCLC.
CI  - Copyright (c) 2023 The Author(s). Published by Wolters Kluwer Health, Inc.
FAU - Duan, Hongtao
AU  - Duan H
AD  - Department of Thoracic Surgery at Tangdu Hospital, Air Force Medical University, 
      Xi'an, Shaanxi.
FAU - Shi, Liang
AU  - Shi L
AD  - Department of Oncology at Beijing Chest Hospital, Capital Medical University, 
      Beijing, China.
FAU - Shao, Changjian
AU  - Shao C
AD  - Department of Thoracic Surgery at Tangdu Hospital, Air Force Medical University, 
      Xi'an, Shaanxi.
FAU - Wang, Yuanyong
AU  - Wang Y
AD  - Department of Thoracic Surgery at Tangdu Hospital, Air Force Medical University, 
      Xi'an, Shaanxi.
FAU - Wang, Zhaoyang
AU  - Wang Z
AD  - Department of Thoracic Surgery at Tangdu Hospital, Air Force Medical University, 
      Xi'an, Shaanxi.
FAU - Ni, Yunfeng
AU  - Ni Y
AD  - Department of Thoracic Surgery at Tangdu Hospital, Air Force Medical University, 
      Xi'an, Shaanxi.
FAU - Zhao, Jinbo
AU  - Zhao J
AD  - Department of Thoracic Surgery at Tangdu Hospital, Air Force Medical University, 
      Xi'an, Shaanxi.
FAU - Sun, Jianyong
AU  - Sun J
AD  - Department of Thoracic Surgery at Tangdu Hospital, Air Force Medical University, 
      Xi'an, Shaanxi.
FAU - Tong, Liping
AU  - Tong L
AD  - Department of Thoracic Surgery at Tangdu Hospital, Air Force Medical University, 
      Xi'an, Shaanxi.
FAU - Lei, Jie
AU  - Lei J
AD  - Department of Thoracic Surgery at Tangdu Hospital, Air Force Medical University, 
      Xi'an, Shaanxi.
FAU - Jiang, Tao
AU  - Jiang T
AD  - Department of Thoracic Surgery at Tangdu Hospital, Air Force Medical University, 
      Xi'an, Shaanxi.
FAU - Liu, Zhe
AU  - Liu Z
AD  - Department of Oncology at Beijing Chest Hospital, Capital Medical University, 
      Beijing, China.
FAU - Yan, Xiaolong
AU  - Yan X
AD  - Department of Thoracic Surgery at Tangdu Hospital, Air Force Medical University, 
      Xi'an, Shaanxi.
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
DEP - 20230901
PL  - United States
TA  - Int J Surg
JT  - International journal of surgery (London, England)
JID - 101228232
RN  - 52CMI0WC3Y (atezolizumab)
SB  - IM
MH  - Female
MH  - Male
MH  - Humans
MH  - Neoadjuvant Therapy
MH  - Cohort Studies
MH  - *Small Cell Lung Carcinoma/drug therapy/surgery
MH  - *Lung Neoplasms/drug therapy/surgery
MH  - Antineoplastic Combined Chemotherapy Protocols/adverse effects
PMC - PMC10498862
COIS- The authors declare that they have no conflict of interest. Sponsorships or 
      competing interests that may be relevant to content are disclosed at the end of 
      this article.
EDAT- 2023/07/10 13:05
MHDA- 2023/10/04 06:43
PMCR- 2023/09/13
CRDT- 2023/07/10 11:05
PHST- 2023/02/20 00:00 [received]
PHST- 2023/05/10 00:00 [accepted]
PHST- 2023/10/04 06:43 [medline]
PHST- 2023/07/10 13:05 [pubmed]
PHST- 2023/07/10 11:05 [entrez]
PHST- 2023/09/13 00:00 [pmc-release]
AID - 01279778-990000000-00491 [pii]
AID - IJS-D-23-00340 [pii]
AID - 10.1097/JS9.0000000000000501 [doi]
PST - epublish
SO  - Int J Surg. 2023 Sep 1;109(9):2641-2649. doi: 10.1097/JS9.0000000000000501.